Biogen's Strategic Acquisitions and Growth Potential: An Analyst's Hold Rating Justification
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $589 From $577, Maintains Buy Rating
Goldman Sachs Adjusts Price Target on Biogen to $342 From $340, Maintains Buy Rating
Goldman Sachs Adjusts Price Target on Gilead Sciences to $71 From $73, Maintains Neutral Rating
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Alnylam Pharmaceuticals Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $255
UBS Raises Price Target on Regeneron Pharmaceuticals to $1,250 From $1,124, Maintains Buy Rating
Biogen Analyst Ratings
Piper Sandler Adjusts Biogen's Price Target to $313 From $335, Keeps Overweight Rating
Vertex Pharmaceuticals Analyst Ratings
Amgen Analyst Ratings
TD Cowen Adjusts Price Target on United Therapeutics to $350 From $270, Maintains Buy Rating
Morgan Stanley Adjusts Price Target on Amgen to $303 From $310
Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183
Morgan Stanley Adjusts Price Target on Gilead Sciences to $74 From $78
Morgan Stanley Adjusts Price Target on Biogen to $311 From $331
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402
United Therapeutics Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings